Tin tức & Cập nhật

The most effective nonsteroidal anti-inflammatory drugs (NSAIDs) for pain and function in patients with osteoarthritis (OA) are etoricoxib 60 mg/day and diclofenac 150 mg/day, suggests a study. However, these medications may not be suitable for those with comorbidities or for long-term use due to the slight increase in the risk of adverse events.

Use of hydroxychloroquine (HCQ) does not contribute to the development of heart failure (HF) in patients with rheumatoid arthritis (RA), a study has shown.

Methotrexate (MTX) plus leflunomide (LEF) demonstrates a relatively good safety profile overall compared with the combination of MTX and sulfasalazine (SSZ) and strategies involving advanced therapies in rheumatoid arthritis (RA), reports a study.

A recent study has shown modest drug survival and primary response of a second biologic disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA) switching due to failure of a nontumour necrosis factor inhibitor (non-TNFi) bDMARD as the first agent.

Current smoking reduces the response of patients with early rheumatoid arthritis (RA) to methotrexate (MTX) in a dose-responsive manner, regardless of concomitant prednisone use, a recent study has found.

The osteoporosis drug alendronate halves the risk of developing type 2 diabetes (T2D) in a nationwide, retrospective, case-control study of nearly 700,000 patients from Denmark.

Superficial needling acupuncture for 4 weeks does not appear to be more effective than nonpenetration sham acupuncture for knee osteoarthritis (OA), a study has found.

The investigational, first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib showed durable efficacy for the treatment of moderate-to-severe plaque psoriasis*, according to the 52-week efficacy analysis results of the POETYK** PSO-1 and POETYK PSO-2 trials presented at EADV 2021.

Among systemic lupus erythematosus patients, SARS-CoV-2-specific immune responses after BNT162b2 vaccination seem to be impaired in the presence of poor baseline humoral immune status, low naïve B cell frequencies, and mycophenolate mofetil (MMF) and methotrexate (MTX) use, according to a study.

The humanized immunoglobulin G1 monoclonal antibody risankizumab conferred long-term benefit for individuals with active psoriatic arthritis (PsA) who had inadequate responses to biologic and conventional synthetic DMARDs* (csDMARDs), according to the open-label extension (OLE) phase findings of the KEEPsAKE 1 and 2 trials presented at EADV 2021.